Skip to main content

Table 4 Subgroup analysis of the relationship between premorbid beta blocker usage and mortality in the intensive care unit

From: Premorbid β1-selective (but not non-selective) β-blocker exposure reduces intensive care unit mortality among septic patients

 

β1-selective BB vs. non-usage

Crude OR

P effect

P interaction

Hypertension

 No

0.46(0.16–1.32)

0.150

0.725

 Yes

0.36(0.16–0.81)

0.013

 

DM

 No

0.46(0.22–0.98)

0.043

0.408

 Yes

0.25(0.08–0.83)

0.024

 

ESRD

 No

0.44(0.23–0.84)

0.012

0.998

 Yes

 

0.998

 

Cirrhosis

 No

0.35(0.18–0.69)

0.002

0.712

 Yes

0.54(0.06–4.77)

0.581

 

COPD

 No

0.31(0.15–0.61)

0.001

0.073

 Yes

1.64(0.30–8.93)

0.569

 

CHF

 No

0.38(0.19–0.76)

0.006

0.706

 Yes

0.27(0.06–1.24)

0.092

 

Arrythmia

 No

0.35(0.17–0.69)

0.003

0.702

 Yes

0.48(0.10–2.25)

0.351

 

CAD

 No

0.31(0.13–0.73)

0.007

0.475

 Yes

0.51(0.18–1.45)

0.206

 

Cancer, solid tumor

 No

0.40(0.20–0.82)

0.012

0.546

 Yes

0.25(0.06–1.05)

0.058

 

Cancer, hematologic

 No

0.44(0.23–0.84)

0.013

0.999

 Yes

 

0.990

 

Septic shock

 No

0.33(0.12–0.92)

0.034

0.576

 Yes

0.48(0.21–1.11)

0.086

 
  1. BB β-blocker, OR odds ratio, DM diabetes mellitus. ESRD end-stage renal disease, CHF chronic heart failure, CAD coronary artery disease, COPD chronic obstruction pulmonary disease